NASDAQ:RYTM - Rhythm Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $42.83
  • Forecasted Upside: 209.49 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$13.84
▲ +0.07 (0.51%)

This chart shows the closing price for RYTM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Rhythm Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RYTM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RYTM

Analyst Price Target is $42.83
▲ +209.49% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Rhythm Pharmaceuticals in the last 3 months. The average price target is $42.83, with a high forecast of $67.00 and a low forecast of $14.00. The average price target represents a 209.49% upside from the last price of $13.84.

This chart shows the closing price for RYTM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 contributing investment analysts is to hold stock in Rhythm Pharmaceuticals. This rating has held steady since July 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/6/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/5/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/3/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
1/1/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
4/1/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
6/30/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
9/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/14/2021The Goldman Sachs GroupUpgradeHold$14.00High
8/4/2021Morgan StanleyLower Price TargetOverweight$57.00 ➝ $54.00High
8/4/2021LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralHigh
8/4/2021Bank of AmericaDowngradeNeutral ➝ Underperform$33.00 ➝ $17.00High
2/25/2021Morgan StanleyBoost Price TargetOverweight$53.00 ➝ $57.00Low
2/18/2021Morgan StanleyBoost Price TargetPositive ➝ Overweight$33.00 ➝ $53.00High
1/27/2021Stifel NicolausBoost Price TargetPositive ➝ Buy$36.00 ➝ $67.00Low
1/27/2021Canaccord GenuityBoost Price TargetBuy$42.00 ➝ $45.00Medium
1/27/2021LADENBURG THALM/SH SHBoost Price TargetPositive ➝ Buy$43.00 ➝ $60.00High
1/5/2021Stifel NicolausReiterated RatingTop PickN/A
11/30/2020Morgan StanleyBoost Price TargetOverweight$30.00 ➝ $33.00Medium
11/30/2020Bank of AmericaDowngradeBuy ➝ Neutral$27.00 ➝ $33.00High
11/3/2020Morgan StanleyLower Price TargetOverweight$31.00 ➝ $30.00High
10/27/2020Canaccord GenuityBoost Price TargetBuy$31.00 ➝ $37.00Medium
10/26/2020Stifel NicolausBoost Price TargetPositive ➝ Buy$31.00 ➝ $36.00High
8/3/2020Needham & Company LLCInitiated CoverageBuy$42.00High
8/3/2020Stifel NicolausReiterated RatingBuy$31.00High
7/17/2020Canaccord GenuityReiterated RatingBuy$31.00High
7/16/2020LADENBURG THALM/SH SHReiterated RatingBuy$43.00Low
6/24/2020Needham & Company LLCInitiated CoverageBuy$42.00Medium
5/4/2020Stifel NicolausReiterated RatingBuy$31.00Low
5/4/2020Needham & Company LLCReiterated RatingBuy$42.00Low
4/15/2020Morgan StanleyLower Price TargetOverweight$33.00 ➝ $31.00Low
3/31/2020LADENBURG THALM/SH SHReiterated RatingBuy$43.00High
3/2/2020Stifel NicolausReiterated RatingBuy$34.00High
1/8/2020The Goldman Sachs GroupInitiated CoverageSell$18.00High
9/25/2019CowenReiterated RatingBuy$40.00High
9/9/2019LADENBURG THALM/SH SHReiterated RatingBuy$43.00Low
7/30/2019LADENBURG THALM/SH SHReiterated RatingBuy$43.00High
7/29/2019Stifel NicolausReiterated RatingBuy$34.00High
7/12/2019Stifel NicolausUpgradeHold ➝ Buy$34.00High
7/8/2019Canaccord GenuityInitiated CoverageBuy ➝ Buy$35.00High
5/5/2019Needham & Company LLCReiterated RatingBuy$42.00Low
5/3/2019LADENBURG THALM/SH SHReiterated RatingBuy$43.00Low
3/28/2019Stifel NicolausSet Price TargetHold$34.00High
3/13/2019LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$43.00Low
3/8/2019CowenReiterated RatingBuy$40.00Low
12/14/2018Needham & Company LLCSet Price TargetBuy$42.00Low
12/13/2018Stifel NicolausReiterated RatingHoldLow
11/11/2018Stifel NicolausReiterated RatingHold$36.00High
9/14/2018Stifel NicolausInitiated CoverageHold$36.00High
9/7/2018Morgan StanleyInitiated CoverageOverweightLow
9/7/2018Morgan StanleySet Price TargetOverweight ➝ Buy$38.00Medium
8/9/2018Needham & Company LLCSet Price TargetBuy$42.00Medium
6/25/2018Needham & Company LLCBoost Price TargetBuy$36.00 ➝ $42.00Low
6/15/2018Needham & Company LLCBoost Price TargetBuy$32.00 ➝ $36.00Low
2/26/2018Needham & Company LLCReiterated RatingBuy$32.00High
11/14/2017CowenReiterated RatingBuy$40.00N/A
11/14/2017Needham & Company LLCReiterated RatingBuy$32.00N/A
10/30/2017Morgan StanleyInitiated CoverageEqual Weight$23.00N/A
10/30/2017Needham & Company LLCInitiated CoverageBuy ➝ Buy$32.00N/A
10/30/2017Bank of AmericaInitiated CoverageBuy$30.00N/A
10/30/2017CowenInitiated CoverageOutperform$40.00N/A
(Data available from 9/28/2016 forward)

News Sentiment Rating

0.50 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/2/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 7 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/30/2021
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 6 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
9/28/2021

Current Sentiment

  • 6 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Rhythm Pharmaceuticals logo
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The firm focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
Read More

Today's Range

Now: $13.84
Low: $13.37
High: $13.88

50 Day Range

MA: $14.31
Low: $11.68
High: $20.02

52 Week Range

Now: $13.84
Low: $11.53
High: $43.26

Volume

2,653 shs

Average Volume

383,196 shs

Market Capitalization

$694.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Rhythm Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Rhythm Pharmaceuticals in the last twelve months: Bank of America Co., Canaccord Genuity, LADENBURG THALM/SH SH, Morgan Stanley, Stifel Nicolaus, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for RYTM.

What is the current price target for Rhythm Pharmaceuticals?

6 Wall Street analysts have set twelve-month price targets for Rhythm Pharmaceuticals in the last year. Their average twelve-month price target is $42.83, suggesting a possible upside of 211.1%. Stifel Nicolaus has the highest price target set, predicting RYTM will reach $67.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $14.00 for Rhythm Pharmaceuticals in the next year.
View the latest price targets for RYTM.

What is the current consensus analyst rating for Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals currently has 1 sell rating, 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in RYTM, but not buy more shares or sell existing shares.
View the latest ratings for RYTM.

How do I contact Rhythm Pharmaceuticals' investor relations team?

Rhythm Pharmaceuticals' physical mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The company's listed phone number is (857) 264-4280 and its investor relations email address is [email protected] The official website for Rhythm Pharmaceuticals is www.rhythmtx.com.